Serotonin signalling in cancer: Emerging mechanisms and therapeutic opportunities
Clinical and Translational Medicine · 2024-07 · 14 (7)
DOI: 10.1002/ctm2.1750 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 28.06.2024. Verfasst von Lulu Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Serotonin, Neoplasms, Signal Transduction. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Plan, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
Background Serotonin (5‐hydroxytryptamine) is a multifunctional bioamine serving as a neurotransmitter, peripheral hormone and mitogen in the vertebrate system. It has pleiotropic activities in central nervous system and gastrointestinal function via an orchestrated action of serotonergic elements, particularly serotonin receptor‐mediated signalling cascades. The mitogenic properties of serotonin have garnered recognition for years and have been exploited for repurposing serotonergic‐targeted drugs in cancer therapy. However, emerging conflicting findings necessitate a more comprehensive elucidation of serotonin's role in cancer pathogenesis. Main body and conclusion Here, we provide an overview of the biosynthesis, metabolism and action modes of serotonin. We summarise our current knowledge regarding the effects of the peripheral serotonergic system on tumourigenesis, with a specific emphasis on its immunomodulatory activities in human cancers. We also discuss the dual roles of serotonin in tumour pathogenesis and elucidate the potential of serotonergic drugs, some of which display favourable safety profiles and impressive efficacy in clinical trials, as a promising avenue in cancer treatment. Key points Primary synthesis and metabolic routes of peripheral 5‐hydroxytryptamine in the gastrointestinal tract. Advanced research has established a strong association between the serotonergic components and carcinogenic mechanisms. The interplay between serotonergic signalling and the immune system within the tumour microenvironment orchestrates antitumour immune responses. Serotonergic‐targeted drugs offer valuable clinical options for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Sun Yat-Sen University, Guangzhou, China.
- Institute of Precision Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Sun Yat-Sen University, Guangzhou, China.
- School of Public Health, Sun Yat-Sen University, Guangzhou, China.
- Department of Gastrointestinal Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
ORCID-Profile: Mei Song
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Plan
- Guangdong Basic and Applied Basic Research Foundation
Zitieren
APA
Chen, L., Huang, S., Wu, X., He, W., & Song, M. (2024). Serotonin signalling in cancer: Emerging mechanisms and therapeutic opportunities. Clinical and Translational Medicine, 14(7). https://doi.org/10.1002/ctm2.1750
Vancouver
Chen L, Huang S, Wu X, He W, Song M. Serotonin signalling in cancer: Emerging mechanisms and therapeutic opportunities. Clinical and Translational Medicine. 2024;14(7). doi:10.1002/ctm2.1750
BibTeX
@article{Chen2024,
author = {Chen, Lulu and Huang, Shuting and Wu, Xiaoxue and He, Weiling and Song, Mei},
title = {Serotonin signalling in cancer: Emerging mechanisms and therapeutic opportunities},
journal = {Clinical and Translational Medicine},
year = {2024},
volume = {14},
number = {7},
doi = {10.1002/ctm2.1750}
}
EUVIMED